Customers at CVS will be able to buy weight loss drug Wegovy at a discount. Cash purchasers can get the Novo Nordisk made product for $499 per month. The pharma company has also recently struck deals with major telehealth companies.
CVS and Novo Nordisk have struck a deal that will see the drug-store chain offering the Wegovy weight-loss drug to customers at a discount.
Approximately 9,000 CVS locations will begin selling Wegovy for $499 per month to customers who pay cash out of pocket. That’s the same rate Novo Nordisk has offered previously through its online pharmacy.
Novo Nordisk has been looking for ways to expand its market share lately. It also recently aligned itself with telehealth companies Hims & Hers, Ro and LifeMD to sell Wegovy at a discount for cash customers.
“As the leader in obesity care for more than a decade, it is our responsibility to continue to work with others across the US healthcare system to find innovative opportunities to meet the needs of these patients and connect them with … Wegovy in a convenient and affordable way,” Dave Moore, president of Novo Nordisk, said in a statement.
Wegovy trails Ozempic in market share. Both drugs are made by Novo Nordisk.
The announcement comes as CVS exceeded analyst expectations in its first-quarter earnings. The company reported earnings per share of $2.25, versus a projected $1.70. Those numbers, however, did not include charges tied to a recent jury verdict against the company’s Omnicare program, which found the unit has filed false claims with Medicare, Medicaid and Tricare, resulting in damages of over $135.5 million.
The company also raised its 2025 guidance to a range of $6 to $6.20 in earnings per share, up from $5.75 to $6.
This story was originally featured on Fortune.com
